Sun Pharmaceutical Industries LtdNSE: SUNPHARMA
Open the Sun Pharmaceutical Industries Ltd page
Follow Sun Pharmaceutical Industries LtdFree account. Get a note when Sun Pharmaceutical Industries Ltd files.
Q4 FY26 results analysis · May 22, 2026

Sun Pharmaceutical Industries Ltd Q4 FY26 Results Analysis: Revenue Grows 11.2%, Margin Compresses in Q4

+26.2%PAT year on year, Rs. 2,714.03 Cr
Cofacto ResearchPublished May 22, 20262 min readPositive read
Quick summary

Sun Pharmaceutical Industries Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 14,611.79 Cr (+12.70% YoY) and PAT growth of +26.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 22, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 14,611.79 Cr (+12.70% YoY)
PAT (Q4)Rs. 2,714.03 Cr (+26.20% YoY)
EBITDA margin27.10% (-160 bps YoY)
Market capRs. 447,715.86 Cr
CMPRs. 1,866.00

Quarter Snapshot

Sun Pharma reported a solid FY26 with 11.2% revenue growth and 130 bps margin expansion despite Q4 margin compression. India market share gains and the US Innovative Medicines crossing $1bn are strategic positives, while US generics pricing pressure and pending FDA facility resolutions remain concerns. The pending Organon acquisition and specialty pipeline catalysts (ILUMYA, UNLOXCYT) provide medium-term alpha visibility.

Key Investment Insights

Key Positives

  • FY26 consolidated revenue grew 11.2% YoY, exceeding management's mid-to-high single-digit guidance.
  • FY26 EBITDA margin expanded 130 bps to 30.3% from 29.0% in FY25.
  • India market share rose 0.3 ppts to 8.4% — highest gain since the Ranbaxy acquisition.
  • US Innovative Medicines crossed $1 billion in FY26 revenue, a strategic milestone.
  • Emerging Markets revenue grew 17.4% YoY in USD terms in Q4, the strongest geography.
  • API segment grew 26.4% YoY in Q4.
  • FY26 normalized CFO of Rs. 124,191.8 Mn exceeded PAT (1.08x), indicating adequate earnings quality.

Risk Factors

  • Q4 EBITDA margin compressed 160 bps YoY to 27.1%, with total expenses growing 15.7% vs revenue growth of 12.7%.
  • US Formulations revenue declined 1.1% YoY in USD terms, driven by generics pricing pressure and lenalidomide competition.
  • Finance costs rose 46.5% YoY in FY26 to Rs. 3,389.1 Mn, outpacing revenue growth.
  • Three manufacturing facilities (Halol, Mohali, Dadra) remain under FDA warning letters with no resolution timeline.
  • Normalized PAT growth slowed to ~4% in FY26 after adjusting for one-time exceptional items.
  • Standalone PAT declined 37.9% YoY in FY26, reflecting reduced domestic intercompany sales.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.